An Open Label, Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Sponsors Baxter Healthcare Corporation
- 08 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2010 Actual patient number is 211 as reported by ClinicalTrials.gov.